| Physiological and pharmacological roles of ABCG2 (BCRP): recent findings in Abcg2 knockout mice MLH Vlaming, JS Lagas, AH Schinkel Advanced drug delivery reviews 61 (1), 14-25, 2009 | 320 | 2009 |
| Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment JS Lagas, RAB van Waterschoot, VACJ van Tilburg, MJ Hillebrand, ... Clinical Cancer Research 15 (7), 2344-2351, 2009 | 218 | 2009 |
| Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation JS Lagas, RAB van Waterschoot, RW Sparidans, E Wagenaar, ... Molecular cancer therapeutics 9 (2), 319-326, 2010 | 208 | 2010 |
| Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice MLH Vlaming, K Mohrmann, E Wagenaar, DR de Waart, RPJO Elferink, ... Journal of Pharmacology and Experimental Therapeutics 318 (1), 319-327, 2006 | 194 | 2006 |
| Brain accumulation of sunitinib is restricted by P‐glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib … SC Tang, JS Lagas, NAG Lankheet, B Poller, MJ Hillebrand, H Rosing, ... International journal of cancer 130 (1), 223-233, 2012 | 184 | 2012 |
| Midazolam metabolism in cytochrome P450 3A knockout mice can be attributed to up-regulated CYP2C enzymes RAB van Waterschoot, AE van Herwaarden, JS Lagas, RW Sparidans, ... Molecular pharmacology 73 (3), 1029-1036, 2008 | 121 | 2008 |
| Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics JS Lagas, ML Vlaming, O van Tellingen, E Wagenaar, RS Jansen, ... Clinical cancer research 12 (20), 6125-6132, 2006 | 113 | 2006 |
| P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 determine the pharmacokinetics of etoposide JS Lagas, L Fan, E Wagenaar, MLH Vlaming, O van Tellingen, JH Beijnen, ... Clinical cancer research 16 (1), 130-140, 2010 | 111 | 2010 |
| Absence of Both Cytochrome P450 3A and P-glycoprotein Dramatically Increases Docetaxel Oral Bioavailability and Risk of Intestinal Toxicity RAB van Waterschoot, JS Lagas, E Wagenaar, CMM van der Kruijssen, ... Cancer research 69 (23), 8996-9002, 2009 | 107 | 2009 |
| P‐glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel JJMA Hendrikx, JS Lagas, H Rosing, JHM Schellens, JH Beijnen, ... International journal of cancer 132 (10), 2439-2447, 2013 | 91 | 2013 |
| Hepatic clearance of reactive glucuronide metabolites of diclofenac in the mouse is dependent on multiple ATP-binding cassette efflux transporters JS Lagas, RW Sparidans, E Wagenaar, JH Beijnen, AH Schinkel Molecular pharmacology 77 (4), 687-694, 2010 | 84 | 2010 |
| Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transport by diclofenac and … JS Lagas, CMM van der Kruijssen, K van de Wetering, JH Beijnen, ... Drug Metabolism and Disposition 37 (1), 129-136, 2009 | 77 | 2009 |
| Liquid chromatography–tandem mass spectrometric assay for diclofenac and three primary metabolites in mouse plasma RW Sparidans, JS Lagas, AH Schinkel, JHM Schellens, JH Beijnen Journal of Chromatography B 872 (1-2), 77-82, 2008 | 77 | 2008 |
| Taxanes: old drugs, new oral formulations RA Jibodh, JS Lagas, B Nuijen, JH Beijnen, JHM Schellens European journal of pharmacology 717 (1-3), 40-46, 2013 | 74 | 2013 |
| Pharmacokinetic assessment of multiple ATP-binding cassette transporters: the power of combination knockout mice JS Lagas, MLH Vlaming, AH Schinkel Molecular interventions 9 (3), 136, 2009 | 71 | 2009 |
| P-glycoprotein limits oral availability, brain penetration, and toxicity of an anionic drug, the antibiotic salinomycin JS Lagas, RW Sparidans, RAB Van Waterschoot, E Wagenaar, ... Antimicrobial agents and chemotherapy 52 (3), 1034-1039, 2008 | 71 | 2008 |
| Individual and combined roles of CYP3A, P‐glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) in the pharmacokinetics of docetaxel RAB van Waterschoot, JS Lagas, E Wagenaar, H Rosing, JH Beijnen, ... International journal of cancer 127 (12), 2959-2964, 2010 | 65 | 2010 |
| Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation J Hendrikx, JS Lagas, E Wagenaar, H Rosing, JHM Schellens, JH Beijnen, ... British journal of cancer 110 (11), 2669-2676, 2014 | 58 | 2014 |
| Liquid chromatography–tandem mass spectrometric assay for sorafenib and sorafenib–glucuronide in mouse plasma and liver homogenate and identification of the glucuronide metabolite RW Sparidans, MLH Vlaming, JS Lagas, AH Schinkel, JHM Schellens, ... Journal of Chromatography B 877 (3), 269-276, 2009 | 40 | 2009 |
| Ritonavir inhibits intratumoral docetaxel metabolism and enhances docetaxel antitumor activity in an immunocompetent mouse breast cancer model JJMA Hendrikx, JS Lagas, JY Song, H Rosing, JHM Schellens, ... International journal of cancer 138 (3), 758-769, 2016 | 36 | 2016 |
